ORGANIZATION
Annual Re-Pricing Key Focus Issue for Japan Pharma Trade Group in FY2018
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) hammered out its project plan for FY2018, beginning in April, at its board of trustees meeting on March 15, with its focus issues including measures to respond to the planned annual…
To read the full story
Related Article
- JPMA to Compile Counterproposal for New PMP Scheme ASAP
February 16, 2018
ORGANIZATION
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





